U.S. markets open in 1 hour 22 minutes
  • S&P Futures

    4,133.50
    -12.75 (-0.31%)
     
  • Dow Futures

    34,094.00
    -89.00 (-0.26%)
     
  • Nasdaq Futures

    13,273.25
    -72.75 (-0.55%)
     
  • Russell 2000 Futures

    2,183.20
    -20.10 (-0.91%)
     
  • Crude Oil

    66.24
    +0.96 (+1.47%)
     
  • Gold

    1,834.30
    -1.80 (-0.10%)
     
  • Silver

    27.52
    -0.15 (-0.53%)
     
  • EUR/USD

    1.2123
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.6240
    0.0000 (0.00%)
     
  • Vix

    22.39
    +2.73 (+13.89%)
     
  • GBP/USD

    1.4129
    -0.0014 (-0.10%)
     
  • USD/JPY

    108.7350
    +0.1150 (+0.11%)
     
  • BTC-USD

    56,348.59
    +1,090.29 (+1.97%)
     
  • CMC Crypto 200

    1,525.16
    +1,282.48 (+528.47%)
     
  • FTSE 100

    6,993.05
    +45.06 (+0.65%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Verrica Pharmaceuticals
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Participants may access a live webcast of the event through the following link:
https://event.on24.com/wcc/r/3173547/7EB680169FF01818435F231AA17B51A2.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com